AIM AIM ImmunoTech Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: AIM

Price (delayed)

$0.4769

Market cap

$23.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.6

Enterprise value

$19.08M

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ...

Highlights
AIM ImmunoTech's revenue has increased by 43% YoY and by 4.7% QoQ
The debt has declined by 14% year-on-year and by 4.3% since the previous quarter
AIM ImmunoTech's quick ratio has plunged by 94% YoY and by 68% from the previous quarter
AIM ImmunoTech's equity has shrunk by 73% YoY and by 55% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://aimimmuno.com/
Peers: TRAW

Key stats

What are the main financial stats of AIM
Market
Shares outstanding
49.9M
Market cap
$23.8M
Enterprise value
$19.08M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.28
Price to sales (P/S)
114.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
94.44
Earnings
Revenue
$202,000
EBIT
-$28.96M
EBITDA
-$28.44M
Free cash flow
-$21.22M
Per share
EPS
-$0.6
Free cash flow per share
-$0.44
Book value per share
$0.21
Revenue per share
$0
TBVPS
$0.35
Balance sheet
Total assets
$19.38M
Total liabilities
$9.15M
Debt
$718,000
Equity
$10.23M
Working capital
$5.9M
Liquidity
Debt to equity
0.07
Current ratio
1.68
Quick ratio
1.51
Net debt/EBITDA
0.17
Margins
EBITDA margin
-14,077.7%
Gross margin
79.2%
Net margin
-14,337.6%
Operating margin
-15,791.1%
Efficiency
Return on assets
-97.9%
Return on equity
-118.3%
Return on invested capital
-389.1%
Return on capital employed
-269.9%
Return on sales
-14,337.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AIM stock price

How has the AIM ImmunoTech stock price performed over time
Intraday
-0.65%
1 week
-22.34%
1 month
27.17%
1 year
-8.29%
YTD
8.41%
QTD
1.25%

Financial performance

How have AIM ImmunoTech's revenue and profit performed over time
Revenue
$202,000
Gross profit
$160,000
Operating income
-$31.9M
Net income
-$28.96M
Gross margin
79.2%
Net margin
-14,337.6%
The operating income has plunged by 60% YoY and by 36% from the previous quarter
The net income has decreased by 49% YoY and by 39% from the previous quarter
AIM ImmunoTech's revenue has increased by 43% YoY and by 4.7% QoQ
The net margin has declined by 33% since the previous quarter and by 4% year-on-year

Growth

What is AIM ImmunoTech's growth rate over time

Valuation

What is AIM ImmunoTech stock price valuation
P/E
N/A
P/B
2.28
P/S
114.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
94.44
The company's EPS has shrunk by 50% YoY and by 40% QoQ
The P/B is 107% higher than the 5-year quarterly average of 1.1 and 90% higher than the last 4 quarters average of 1.2
AIM ImmunoTech's equity has shrunk by 73% YoY and by 55% QoQ
AIM's P/S is 61% below its 5-year quarterly average of 294.2 and 16% below its last 4 quarters average of 136.7
AIM ImmunoTech's revenue has increased by 43% YoY and by 4.7% QoQ

Efficiency

How efficient is AIM ImmunoTech business performance
The return on invested capital has dropped by 200% year-on-year and by 73% since the previous quarter
The ROE has plunged by 179% YoY and by 80% from the previous quarter
AIM's ROA has shrunk by 141% YoY and by 64% QoQ
The company's return on sales fell by 33% QoQ and by 4% YoY

Dividends

What is AIM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AIM.

Financial health

How did AIM ImmunoTech financials performed over time
The total assets is 112% greater than the total liabilities
AIM's current ratio has dropped by 94% year-on-year and by 65% since the previous quarter
AIM ImmunoTech's quick ratio has plunged by 94% YoY and by 68% from the previous quarter
The debt is 93% smaller than the equity
AIM's debt to equity has surged by 133% since the previous quarter
AIM ImmunoTech's equity has shrunk by 73% YoY and by 55% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.